HOME >> BIOLOGY >> NEWS
UC Santa Barbara discovers cell survival gene may lead to treatments for degenerative diseases

(Santa Barbara, Calif.) Our cells are constantly making life and death decisions. A new gene that controls this life or death switch and protects cells from dying has been discovered by researchers at the University of California, Santa Barbara, as reported in the August 28 edition of the scientific journal Nature.

The discovery may provide scientists with new means for identifying drugs that combat degenerative diseases such as Lou Gehrig's disease (ALS), the destructive effects of stroke and heart diseases, autoimmune diseases, and cancer.

Chilling though it sounds, our cells are poised on the brink of death. Yet the ongoing death of some of our cells is actually essential for us to live. "Death, that is to say cell death, is a key player in biology and medicine," said Joel Rothman, associate professor of Molecular, Cellular and Developmental Biology, and leader of the UCSB research team. "Cells often commit suicide so that others may live. This is the ultimate example of altruism at the cellular level."

Why would a cell kill itself off? "Programmed cell death is one of the first lines of defense against cancer and infection by invaders such as viruses," notes Rothman. "Ironically, the failure of a wayward cell to die can actually lead to death of the individual."

By killing itself off, a malignant or infected cell can prevent the disease from spreading. However, the throttle on cell death must be carefully set. "While death is a necessary part of our survival, too much cell death is disastrous," said Rothman "That is what happens in degenerative diseases."

The gene identified by Rothman and UCSB postdoctoral researchers Tim Bloss and Eric Witze is called ICD-1 (inhibitor of cell death gene 1). It prevents normal cells from committing suicide. "As often happens in research, we were looking into an entirely different process when we stumbled across this cell death gene,"
'"/>

Contact: Eileen Conrad
eileen.conrad@ia.ucsb.edu
805-893-8726
University of California - Santa Barbara
27-Aug-2003


Page: 1 2 3

Related biology news :

1. UC Santa Barbara donates discovery to OneWorld Health that may speed disease treatment
2. Chemical society convenes regional meeting in Santa Barbara, October 28-31
3. Webcast will ensure broad public access to the UC Santa Cruz Public Forum on Human Genome Research
4. UC Santa Cruz Public Forum on the Human Genome
5. Coastal research project at UC Santa Cruz receives major boost in funding
6. UC Davis, Santa Barbara get $6 million to help estuaries
7. Future uses of MicroElectricalMechanical (MEM) systems to be featured at Santa Clara show
8. USGS Scientists To Speak On Rare Plants And Invasive Species At Santa Barbara Symposium
9. LSU researcher discovers new bird
10. MIT team discovers memory mechanism
11. OHSU team discovers compound that lacks estrogens risks

Post Your Comments:
(Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: